Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis

被引:0
|
作者
Draelos, Zoe Diana [1 ]
Traub, Michael [2 ]
Gold, Michael H. [3 ]
Green, Lawrence J. [4 ]
Amster, Mark [5 ]
Barak-Shinar, Deganit [6 ]
Kircik, Leon H. [7 ,8 ,9 ,10 ]
机构
[1] Dermatol Consulting Serv PLLC, High Point, NC USA
[2] Hawaii Integrat Oncol Hoo Lokahi, Kailua, HI USA
[3] Tennessee Clin Res Ctr, Nashville, TN USA
[4] George Washington Univ, Sch Med, Washington, DC USA
[5] Metro Boston Clin Partners LLC, Boston, MA USA
[6] Kamedis Ltd, Tel Aviv, Israel
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[8] Indiana Univ, Med Ctr, Indianapolis, IN 46202 USA
[9] Physicians Skin Care PLLC, Louisville, KY 40217 USA
[10] DermRes PLLC, Louisville, KY 40241 USA
关键词
SKIN; PSORIASIS; BARRIER;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: The study was conducted to determine the efficacy of the botanical combination incorporated in Kamedis Eczema Therapy Cream (the test product) for children with mild to moderate atopic dermatitis. Design: The study was designed as an interventional, multi-center, double-blind, randomized, controlled study. Setting: Children subjects were a sub-population of the 108 combined population of adults and children evenly randomly divided into three treatment groups: test product, vehicle, and comparator. The vehicle used was the identical test product without the botanical combination while the comparator was a leading OTC brand in the US market. All three groups used the same Kamedis body wash followed by one of the three randomized treatment creams for the affected areas. Participants: Thirty-nine (39) children subjects with uncomplicated, stable, mild to moderate atopic dermatitis were recruited and qualified for the study, 24 female and 15 male, ages varying between 3 and 18. Measurements: Investigators assessed the severity of each subject using the Investigator Global Assessment (IGA), affected Body Surface Area (BSA) extent evaluated parameters at each of the visit days 0, 7 14, and 28. Subjective symptoms of pruritus and insomnia were evaluated by the patient or their legal guardian. The SCORAD and EASI indexes were calculated based on the collected parameters. Results: The test product demonstrated an improvement in all evaluated and calculated clinical parameters over the vehicle at the end of the treatment duration, proving the validation that the test product is much more effective and beneficial than the vehicle. The test product reached 40% of 'clear' IGA subjects out of the enrolled subjects and 60% out of the 'clear' and 'almost clear' IGA subjects comparing to 8% and 38%, respectively, with the vehicle, presenting a clear advantage over the vehicle. The BSA improvement comparison analysis of the test product over the vehicle yielded P value of less than 0.05, which is statistically significant. The SCORAD and EASI indexes also showed an advantage of the test product versus the vehicle at week 4. Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [1] Validation of Botanical Treatment Efficiency for Adults and Children Suffering from Mild to Moderate Atopic Dermatitis
    Draelos, Zoe Diana
    Traub, Michael
    Gold, Michael H.
    Green, Lawrence J.
    Amster, Mark
    Barak-Shinar, Deganit
    Kircik, Leon H.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (06) : 557 - 561
  • [2] 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
    Cheape, Alice C.
    Murrell, Dedee F.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (05) : 415 - 423
  • [3] The Frequency and Intensity of Topical Pimecrolimus Treatment in Children with Physician-Confirmed Mild to Moderate Atopic Dermatitis
    Kapoor, Roger
    Hoffstad, Ole
    Bilker, Warren
    Margolis, David J.
    PEDIATRIC DERMATOLOGY, 2009, 26 (06) : 682 - 687
  • [4] Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis
    Cohen, Bernard
    CLINICAL PEDIATRICS, 2007, 46 (01) : 7 - 15
  • [5] Efficacy of a Cosmetic Treatment in Decreasing the Mild-to-Moderate Atopic Dermatitis in Babies, Children, and Adults: A Pilot Study
    Nobile, Vincenzo
    Zanoletti, Valentina
    Pisati, Marta
    Cestone, Enza
    COSMETICS, 2023, 10 (04)
  • [6] Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis
    Lynde, Charles W.
    Bergman, James
    Fiorillo, Loretta
    Guenther, Lyn
    Keddy-Grant, Jill
    Landells, Ian
    Marcoux, Danielle
    Ramien, Michele
    Rehmus, Wingfield
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2019, 23 : 3S - 13S
  • [7] Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
    Eichenfield, LF
    Lucky, AW
    Boguniewicz, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (04) : 495 - 504
  • [8] Treatment of Pruritus in Mild-to-Moderate Atopic Dermatitis With a Topical Non-Steroidal Agent
    Veraldi, Stefano
    De Micheli, Paolo
    Schianchi, Rossana
    Lunardon, Luisa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2009, 8 (06) : 537 - 539
  • [9] Steroid-sparing effect of an emollient in the treatment of mild to moderate atopic dermatitis in children
    Msika, P
    Piccardi, N
    Choulot, JC
    Chadoutaud, B
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P10 - P10
  • [10] Phase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic Dermatitis
    Lynde, Charles
    Poulin, Yves
    Tan, Jerry
    Lomaga, Mark
    Loo, Wei-Jing
    Carbonneau, Diane
    Delorme, Isabelle
    Grimard, Doria
    Sampalis, John
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (10) : 1091 - 1097